Bayer and ar-GEN-X to collaborate on drug discovery
- Bayer will start using the SIMPLE Antibody Platform developed by arGEN-X to aid drug discovery and development.
- arGEN-X focuses on developing therapeutic antibodies to be used for the treatment of cancer and autoimmune diseases.
- asGEN-X also have collaborative relationships with Shire and with Eli Lilly.
Under the agreement, Bayer will submit targets to ar-GEN-X, which will apply the targets to its platform. Bayer will be responsible for preclinical and clinical development, as well as commercialization. Bayer is paying a technology access fee and will pay milestone fees as development progresses.